Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NewKI, one of UK’s largest observational studies of incident chronic kidney disease (CKD) in general practice, gets underway this month, involving 3,205 Oxfordshire residents and led by Oxford University researchers.

Over the next two years, the New onset Kidney Impairment (NewKI) study will work with 13 Oxfordshire GP surgeries to investigate how people over the age of 60 progress from mild to more severe forms of CKD. This could help doctors to better identify and treat those at risk.

Kidney function declines slowly with age, and around 1 in 10 people have mild chronic kidney disease. Recognised as an international health issue by the World Health Organisation and responsible for 850,000 deaths globally, CKD is associated with an increased risk of developing cardiovascular diseases such as stroke, heart failure and sudden death.

However, very little is known about how many people in the UK have CKD, or the factors that increase someone’s risk of developing the condition and progressing onto more severe forms of kidney decline.

Find out more (Nuffield Department of Primary Care Health Sciences website)

Similar stories

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.